Results 201 to 210 of about 1,221,083 (383)

Nanomedicines for chronic non-infectious arthritis: the clinician's perspective.

open access: yesNanomedicine : nanotechnology, biology, and medicine, 2012
I. Rubinstein, G. Weinberg
semanticscholar   +1 more source

A phase 2 trial of hydroxychloroquine in individuals at risk for rheumatoid arthritis

open access: yesArthritis &Rheumatology, Accepted Article.
Background Individuals with serum elevations of anti‐cyclic citrullinated peptide (anti‐CCP) antibodies are at increased risk for future rheumatoid arthritis (RA). No pharmacologic interventions have been approved for the prevention of RA in such ‘at‐risk’ individuals. However, hydroxychloroquine (HCQ) is used without supporting clinical trial evidence.
Kevin D. Deane   +33 more
wiley   +1 more source

Pathological and bacteriological findings in sows, finisher pigs, and piglets, being culled for lameness. [PDF]

open access: yesPorcine Health Manag
Jacobson M   +8 more
europepmc   +1 more source

ROS‐induced modifications of fibrin clots connect immune responses to atherothrombosis in systemic lupus erythematosus

open access: yesArthritis &Rheumatology, Accepted Article.
Objective Cardiovascular events are major determinants of morbidity and mortality in systemic lupus erythematosus (SLE), particularly in patients with renal involvement. While oxidative stress has been implicated in driving vascular and renal damage in SLE, the specific mechanisms remain unclear.
Matteo Becatti   +13 more
wiley   +1 more source

Inflammatory osteolysis: A conspiracy against bone [PDF]

open access: yes, 2017
Abu-Amer   +36 more
core   +2 more sources

Cytokine pathways driving diverse tissue pathologies in rheumatoid arthritis

open access: yesArthritis &Rheumatology, Accepted Article.
Rheumatoid arthritis is a complex systemic disorder characterised primarily by articular inflammation and destruction with associated functional loss and reduced quality of life. RA is also associated with extra‐articular disease e.g. of the lung with potentially devastating clinical consequences.
Aurelie Najm   +2 more
wiley   +1 more source

Comparative efficacy and safety of anakinra and canakinumab in patients with VEXAS syndrome – an international multicenter study

open access: yesArthritis &Rheumatology, Accepted Article.
Objectives The aim of this study was to compare differences in clinical response, drug survival, and adverse event rates between anakinra and canakinumab in VEXAS syndrome. Methods This multicenter international study includes VEXAS patients from France, Israel, and Italy treated with IL1 inhibition (IL1i).
Tali Eviatar   +35 more
wiley   +1 more source

RITUXIMAB REFRACTORY NON INFECTIOUS NECROTIZING SCLERITIS IN RHEUMATOID ARTHRITIS: WHAT TO DO NEXT

open access: bronze, 2023
Saulo Cardoso Xavier Filho   +15 more
openalex   +1 more source

Home - About - Disclaimer - Privacy